-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10

Benzinga·10/23/2026 09:41:58
Listen to the news
BTIG analyst Julian Harrison maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $58 to $10.